[Clinical complications in a series of patients with anticardiolipin antibodies].

An analysis was made of clinical complications, determined with objective methods, in 68 patients at the University Clinic of Navarra with the clinical suspicion of antiphospholipid syndrome (APS) and presence of anticardiolipin antibodies (ACA). Patients with IgG higher than 23 GPL were considered for the study. The most prevalent pathology was thrombosis: venous thrombosis (42.6%) and arterial thrombosis (22%). Other complications were abortions (23.8% of the 42 women) and thrombocytopenia (12.1%). With respect to the localisation of venous thrombosis, predominance corresponded to lower extremities (51.7%), followed by superficial thrombophlebitis (27.5%) and pulmonary thromboembolism (20.6%). Among the arterial complications, the most frequent were cerebrovascular disease (86.6 %) and coronary disease (13.4%). There was no correlation between the presence of high values of ACA and the prevalence or severity of clinical manifestations. In the series of patients with ACA IgG>23 GPL, we appreciated a high percentage of venous and arterial thrombosis detected with objective methods. The presence of ACA constitutes a prothrombotic risk factor

[1]  T. Barbui,et al.  Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. , 2003, Blood.

[2]  L. Regan,et al.  Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. , 2002, Obstetrics and gynecology.

[3]  M. Greaves,et al.  Antiphospholipid Syndrome in Pregnancy: A Randomized, Controlled Trial of Treatment , 2002, Obstetrics and gynecology.

[4]  N. Magy,et al.  Valeur relative des différents anticorps antiphospholipides détectés dans un service de médecine interne : étude rétrospective chez 124 patients , 2002 .

[5]  T. Koike,et al.  Anticardiolipin Antibody Assay: a Methodological Analysis for a better Consensus in Routine Determinations , 2001, Thrombosis and Haemostasis.

[6]  J. Arnout,et al.  Antiphospholipid Syndrome: Diagnostic Aspects of Lupus Anticoagulants , 2001, Thrombosis and Haemostasis.

[7]  R. Sellers,et al.  Therapy in ESRD patients with antiphospholipid antibody syndrome. , 2001, Transplantation proceedings.

[8]  A. Moss,et al.  Anticardiolipin Antibodies and Recurrent Coronary Events: A Prospective Study of 1150 Patients , 2000, Circulation.

[9]  José A Fernández,et al.  Cardiolipin is a normal component of human plasma lipoproteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  J. Weinberger,et al.  Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. , 1999, Stroke.

[11]  W A Wilson,et al.  International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. , 1999, Arthritis and rheumatism.

[12]  A. Felten,et al.  Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia , 1998, European journal of haematology.

[13]  E. Svenungsson,et al.  Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group. , 1998, The American journal of medicine.

[14]  J. Provenzale,et al.  Systemic thrombosis in patients with antiphospholipid antibodies: lesion distribution and imaging findings. , 1998, AJR. American journal of roentgenology.

[15]  G. Hughes,et al.  Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients , 1998, Lupus.

[16]  S. Levine,et al.  IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. , 1997, Stroke.

[17]  A. Shiran,et al.  Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. , 1996, The American journal of medicine.

[18]  T. Barbui,et al.  Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. , 1996, The American journal of medicine.

[19]  P. Brill-Edwards,et al.  Antiphospholipid antibodies and venous thromboembolism. , 1995, Blood.

[20]  S. Levine,et al.  Recurrent stroke and thrombo‐occlusive events in the antiphospholipid syndrome , 1995, Annals of neurology.

[21]  L. Tenkanen,et al.  Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. , 1995, Circulation.

[22]  E. Harris,et al.  The antiphospholipid syndrome , 1995, Clinical reviews in allergy & immunology.

[23]  T. Brighton,et al.  Antiphospholipid antibodies and thrombosis. , 1994, Bailliere's clinical haematology.

[24]  R. Brey.  Anticardiolipin antibodies are an independent risk factor for first ischemic stroke , 1993, Neurology.

[25]  M. Stampfer,et al.  Anticardiolipin Antibodies and the Risk for Ischemic Stroke and Venous Thrombosis , 1992, Annals of Internal Medicine.

[26]  C. Chesterman,et al.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Kushner,et al.  Prospective study of anticardiolipin antibodies in stroke. , 1990, Stroke.

[28]  G. Hughes,et al.  The “Primary” Antiphospholipid Syndrome: Major Clinical and Serological Features , 1989, Medicine.

[29]  G. Hughes.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. , 1983, British medical journal.